STI 571 strengthens its standing in CML

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1273, 2001-01, pp. : 7-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

STI-571 active and well tolerated in CML and ALL

By  

Inpharma, Vol. 1, Iss. 1283, 2001-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

STI 571 teams up to trick CML cells into self-betrayal

By  

Inpharma, Vol. 1, Iss. 1280, 2001-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

STI 571 active in patients with rare GI cancer

By  

Inpharma, Vol. 1, Iss. 1291, 2001-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

The Role of the Tyrosine Kinase Inhibitor STI571 in the Treatment of Cancer

By  

Current Cancer Drug Targets, Vol. 1, Iss. 1, 2001-05 ,pp. : 49-57

Bentham Science Publishers

Access to resources Recommend Favorite

Imatinib (STI571) Resistance in Chronic Myelogenous Leukemia: Molecular Basis of the Underlying Mechanisms and Potential Strategies for Treatment

By  

Mini Reviews in Medicinal Chemistry, Vol. 4, Iss. 3, 2004-03 ,pp. : 285-299

Bentham Science Publishers

Access to resources Recommend Favorite